"10.1371_journal.pone.0144787","plos one","2015-12-23T00:00:00Z","Hannah Karlsson; Emma Svensson; Camilla Gigg; Malin Jarvius; Ulla Olsson-Str√∂mberg; Barbara Savoldo; Gianpietro Dotti; Angelica Loskog","Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden; Department of Medical Sciences, Uppsala University, Uppsala, Sweden; Section of Hematology, Uppsala University Hospital, Uppsala, Sweden; Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas, United States of America","Conceived and designed the experiments: HK CG BS GD AL. Performed the experiments: HK ES CG BS GD MJ. Analyzed the data: HK MJ BS GD AL. Contributed reagents/materials/analysis tools: MJ UOS BS GD AL. Wrote the paper: HK BS AL.","The authors have the following interests: Dr Loskog is the CEO and board member of Lokon Pharma AB, scientific advisor at NEXTTOBE AB, chairman of Vivolux AB and RePos Pharma AB and board member of Chemilia AB. Further she has a royalty agreement with Alligator Biosciences AB and Lokon Pharma AB. Dr Jarvius spouse is funder, stockholder and board member as well as employed by Qlinea AB. Neither of these conflicts are connected to CAR T cells. Dr. Dotti and Dr. Savoldo have ownership interest (including patents Targeting the tumor microenvironment using manipulated NKT cells with application number: 20140255363, Immunotherapy of cancer using genetically engineered GD2-specific T cells with application number: 20140004132 and Engineered CD19-specific T lymphocytes that coexpress IL-15 and an inducible caspase-9 based suicide gene for the treatment of B-cell malignancies with application number: 20130071414) in the field of T cell and gene-modified T-cell therapy for cancer but those are not directly connected to the CAR T cells presented herein. The Center for Cell and Gene Therapy has a collaborative research agreement with Celgene and Bluebird bio. The remaining authors have no conflict of interest. There are no further patents, products in development or marketed products to declare. This did not alter the authors adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","12","Hannah Karlsson","HK",8,TRUE,5,6,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
